Daughaday W H, Barbano D M
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Mo.
JAMA. 1990;264(8):1003-5.
Complex, biologically active proteins (eg, enzymes and hormones) can be manufactured safely and cost-effectively through applications of biotechnology. Some of these proteins (eg, human insulin, human somatotropin, rennet for cheese manufacture) are currently approved for medical or food processing applications. Bovine somatotropin (bST) for lactating dairy cattle is another product that can be produced via biotechnology and may allow dairy farmers to produce milk at a lower cost. In 1985, based on an evaluation of toxicological data, the Food and Drug Administration concluded that milk and meat from bST-supplemented cows was safe and wholesome. The Food and Drug Administration has authorized the use of milk and meat from bST-supplemented cows in the commercial food supply. Its evaluation of the impact of bST supplementation on the long-term health of dairy cattle is near completion, and bST may be approved for commercial use in early 1991.
通过生物技术的应用，可以安全且经济高效地制造复杂的生物活性蛋白质（如酶和激素）。其中一些蛋白质（如人胰岛素、人生长激素、用于奶酪制造的凝乳酶）目前已获批用于医疗或食品加工应用。用于泌乳奶牛的牛生长激素（bST）是另一种可通过生物技术生产的产品，它可能使奶农以更低的成本生产牛奶。1985年，基于对毒理学数据的评估，美国食品药品监督管理局得出结论，来自补充了bST的奶牛的牛奶和肉类是安全且有益健康的。美国食品药品监督管理局已批准在商业食品供应中使用来自补充了bST的奶牛的牛奶和肉类。其对补充bST对奶牛长期健康影响的评估即将完成，bST可能在1991年初获批用于商业用途。
